Gilead Sciences (GILD) Stock: Buy, Sell, or Hold?

GILD - Gilead Sciences Inc

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
$144.74
-2.76 (-1.87%) ▼
5d: -4.1%
30d: -3.26%
90d: +11.67%
WAIT
LOW Confidence
Protect Your GILD Gains
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 29, 2026 24d

Get Alerted When GILD Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 MIXED SIGNALS: GILD shows conflicting indicators. Wait for confirmation before entering.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$199.53
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$123.89
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.4x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: GILD is currently trading at $144.74, which is considered oversold relative to its 30-day fair value range of $146.12 to $151.01. The stock's valuation (Forward PE: 14.6) is in line with its historical norms (14.4). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, GILD is in a strong uptrend. The price is currently testing key support at $144.00. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD
Historical Trading Range $146.12 - $151.01
Company Quality Score 46/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 75.7%

Protect Your Profits

Holding GILD? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (42/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($158.65)
  • NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
  • WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $146.12 - $151.01
Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $144.00
Resistance Level $154.20
Current Trend Strong Uptrend
Technical data as of Oct 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 14.64
Wall Street Target $158.65 (+9.6%)
Revenue Growth (YoY) 10.2%
Earnings Growth (YoY) 54.8%
Profit Margin -10.6%
Valuation Premium vs History +0.7% premium
PE vs Historical 14.6 vs 14.4 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +0.7% (market-implied from PE analysis)
1-Year Target $145.75 (+1%)
2-Year Target $146.77 (+1%)
3-Year Target $147.80 (+2%)
3-Yr Target (if PE normalizes) (PE: 15→14) PE COMPRESSION $145.41 (+1%)
Earnings growth offset by PE compression
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: October 04, 2026 2:23 AM ET
Data refreshes hourly during market hours. Next update: 3:23 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrew D Dickinson SELL 3000 shares 2026-04-15
Johanna Mercier SELL 3000 shares 2026-04-15

Unlock Insider Activity

See real-time buying/selling by company executives for GILD.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - General Stocks

Top-rated stocks in Drug Manufacturers - General by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
LLY
Eli Lilly and Company
STRONG BUY
31 analysts
$1325 48 HOLD
ABBV
AbbVie Inc
BUY
28 analysts
$279 57 HOLD
AMGN
Amgen Inc
HOLD
32 analysts
$389 55 HOLD
BIIB
Biogen Inc
HOLD
37 analysts
$238 48 HOLD
MRK
Merck & Company Inc
BUY
26 analysts
$154 55 HOLD

Advanced GILD Option Strategies

Professional options setups generated by AI based on today's GILD price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for GILD

GILD Technical Chart GILD Price Prediction GILD Earnings Date GILD Investment Advisor GILD Fair Price Analyzer GILD Options Advisor GILD Options Chain GILD Options Analysis GILD Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals